Olio Labs utilizes artificial intelligence and machine learning to develop combination therapeutics that account for the complex interactions of proteins in the human body, rather than focusing on single-target treatments. This approach enables the identification of more effective therapies with reduced side effects for challenging diseases by automating the discovery and development process.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
UVZVFounders
Product
Problem
Traditional drug development focuses on single-target treatments, neglecting the complex interactions of proteins within the human body. This approach can lead to less effective therapies and increased side effects, especially for complex diseases.
Solution
Olio Labs is developing combination therapeutics using artificial intelligence and machine learning to account for the intricate network of protein interactions. Their platform, the Combination Design Engine, analyzes thousands of interacting proteins to identify drug combinations that are more effective and have fewer side effects than single-target approaches. By automating the discovery and development process, Olio Labs aims to create better therapies for challenging diseases. The platform designs combination therapies that deliver better outcomes with fewer side effects.
Target Audience
The primary target audience includes individuals and healthcare providers seeking more effective treatments for complex diseases with fewer side effects.
Features
- AI-powered platform analyzes thousands of interacting proteins.
- Combination Design Engine identifies synergistic drug combinations.
- Focus on developing therapies with improved efficacy and reduced side effects.
- Automation of the drug discovery and development process.